An update on the pharmacoeconomics of antifungal pharmacotherapy |
| |
Authors: | Sarah M Wieczorkiewicz Jacqueline Jourjy Larry Danziger |
| |
Institution: | (1) Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, 833 S. Wood Street, Room 164 (M/C 886), Chicago, IL 60612, USA |
| |
Abstract: | The incidence and severity of invasive fungal infections are on the rise and they pose a risk of significant morbidity and
mortality. The cost burden of fungal infections in the United States is high. There are many newer, less toxic antifungal
agents to manage these challenging infections; however, these agents also carry a high cost of their own. When considering
an antifungal agent for a specific patient, it is important to consider safety, efficacy, and cost, thus making it essential
to continually evaluate the antifungal pharmacoeconomic literature to assist in the therapeutic decision-making process for
patients with invasive fungal infections. Unfortunately, there is a lack of pharmacoeconomic studies addressing the costs
associated with the treatment and prevention of fungal infections. Future large-scale clinical studies should include pharmacoeconomic
analyses and end points that encompass all costs associated with antifungal drug use, not solely drug acquisition costs. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|